MedDay is a French biotech company in the treatment of neuro-metabolic diseases. Founded in 2011 by Frédéric Sedel and Guillaume Brion, MedDay relies on the work of Dr Frédéric Sedel, a neuroscientist at La Pitié Salpêtrière Hospital (Paris), who has been carrying out pioneering research in neurology to identify rare hereditary metabolic diseases in adults for more than a decade. Dr Frédéric Sedel’s research has led to the identification of new treatments and diagnostic tools for diseases in a field where few treatments, if any, are available. The company is currently incubated at l’Institut du Cerveau et de la Moelle épinière in Paris (ICM).

Biopharmaceuticals

Antoine Papiernik

Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, ProQR, Shockwave Medical,  NovusPharma (then sold to CTI), Movetis (then sold to Shire), Mainstay, Pixium Vision and...